Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lipid Sciences has received two key patents from the US Patent and Trademark Office that cover fundamental aspects of the company's viral immunotherapy platform.
Subscribe to our email newsletter
These two patents are said to cover the basic composition of viral particles resulting from Lipid Sciences’s proprietary viral delipidation process.
Lewis Meyer, president and CEO of Lipid Sciences, said: “The validation by the US Patent and Trademark Office of the novelty of Lipid Sciences’s viral delipidation as a technique for vaccine development not only represents a new direction in HIV vaccine research but also adds important assets to Lipid Sciences’s broad base of intellectual property.”